

JEREMIAH B. FRUEAUF
ATTORNEY
(202) 772-8506
JFRUEAUF@SGKF.COM



February 4, 2011

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Confirmation No. 2306
Art Unit 1646
Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/587,714; 371(c) Date: June 4, 2007
For: **Treatment of Conditions Involving Dopaminergic Neuronal
Degeneration Using Nogo Receptor Antagonists**
Inventors: RELTON *et al.*
Our Ref: 2681.0450001/EJH/JBF

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Fifth Supplemental Information Disclosure Statement;
2. Form PTO/SB/08a (1 sheet) listing 1 document (FP16);
3. Form PTO/SB/08b (1 sheet) listing 4 documents (NPL44-NPL47); and
4. Copies of cited documents (FP16 and NPL44-NPL47).

The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in dark ink, appearing to read 'JBF' with a stylized flourish.

Jeremiah B. Frueauf
Attorney for Applicants
Registration No. 66,638

JBF/amb
Enclosures

1317038_1.doc